NASDAQ:XBIO Xenetic Biosciences (XBIO) Stock Price, News & Analysis $2.26 +0.02 (+0.67%) As of 12:41 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Xenetic Biosciences Stock (NASDAQ:XBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xenetic Biosciences alerts:Sign Up Key Stats Today's Range$2.19▼$2.2750-Day Range$2.19▼$4.6752-Week Range$1.87▼$13.93Volume6,007 shsAverage Volume43,203 shsMarket Capitalization$5.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Xenetic Biosciences, Inc. is a clinical-stage biotechnology company focused on developing targeted therapeutics for cancer and other serious diseases. The company’s research and development activities center on immuno-oncology, cell therapy, and proprietary drug-development technologies intended to improve the effectiveness, safety, or delivery of existing and emerging treatments. Xenetic’s technology portfolio has included XCART, an investigational personalized cell-therapy platform designed to use a patient’s own immune cells to target tumor-associated antigens. The company has also advanced oncology drug candidates and related research programs, including XBIO-101, an investigational compound studied for potential use in cancer treatment. These programs remain subject to clinical testing and regulatory review. Based in the United States, Xenetic Biosciences has historically pursued development through internal research, clinical programs, and collaborations with biotechnology and pharmaceutical organizations. Its products are investigational and are not broadly marketed or approved for commercial use unless otherwise authorized by applicable regulators.AI Generated. May Contain Errors. Read More Xenetic Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreXBIO MarketRank™: Xenetic Biosciences scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXenetic Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXenetic Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Xenetic Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenetic Biosciences is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenetic Biosciences is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenetic Biosciences has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Xenetic Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.06% of the float of Xenetic Biosciences has been sold short.Short Interest Ratio / Days to CoverXenetic Biosciences has a short interest ratio ("days to cover") of 0.45, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xenetic Biosciences has recently increased by 10.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXenetic Biosciences does not currently pay a dividend.Dividend GrowthXenetic Biosciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for XBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Xenetic Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders7.60% of the stock of Xenetic Biosciences is held by insiders.Percentage Held by Institutions15.12% of the stock of Xenetic Biosciences is held by institutions.Read more about Xenetic Biosciences' insider trading history. Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XBIO Stock News HeadlinesReviewing Allarity Therapeutics (NASDAQ:ALLR) & Xenetic Biosciences (NASDAQ:XBIO)September 27, 2026 | americanbankingnews.comXenetic To Acquire Santersus In All-Stock Deal To Advance NET-Focused PipelineSeptember 17, 2026 | rttnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 5 at 1:00 AM | Banyan Hill Publishing (Ad)Xenetic Biosciences y Santersus AG acuerdan crear un líder global en terapias contra las NETSeptember 16, 2026 | es.finance.yahoo.comXenetic Biosciences announces all-stock merger with Santersus, leaving existing shareholders with 15% stakeSeptember 16, 2026 | msn.comXenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks TranscriptSeptember 16, 2026 | seekingalpha.comXenetic Biosciences Inc.September 5, 2026 | barrons.comXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of ...June 4, 2026 | finance.yahoo.comSee More Headlines XBIO Stock Analysis - Frequently Asked Questions How have XBIO shares performed this year? Xenetic Biosciences' stock was trading at $2.17 at the beginning of the year. Since then, XBIO stock has increased by 3.2% and is now trading at $2.24. How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences, Inc. (NASDAQ:XBIO) released its quarterly earnings results on Thursday, August, 6th. The company reported ($0.41) earnings per share (EPS) for the quarter. The firm had revenue of $0.66 million for the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative trailing twelve-month return on equity of 40.62%. When did Xenetic Biosciences' stock split? Xenetic Biosciences's stock reverse split on the morning of Monday, May 15th 2023.The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Xenetic Biosciences? Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xenetic Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenetic Biosciences investors own include FuelCell Energy (FCEL), OPKO Health (OPK), VBI Vaccines (VBIV), Bionano Genomics (BNGO), NIO (NIO), Sorrento Therapeutics (SRNE) and Company Calendar Last Earnings8/06/2026Today10/05/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, XBIO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XBIO CIK1534525 Webwww.xeneticbio.com Phone781-778-7720FaxN/AEmployees2Year Founded2011Profitability EPS (Trailing Twelve Months)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.68 million Net Margins-75.90% Pretax Margin-75.90% Return on Equity-40.62% Return on Assets-34.97% Debt Debt-to-Equity RatioN/A Current Ratio7.43 Quick Ratio7.43 Sales & Book Value Annual Sales$2.98 million Price / Sales1.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.23 per share Price / Book0.70Miscellaneous Outstanding Shares2,290,000Free Float2,117,000Market Cap$5.16 million OptionableNot Optionable Beta2.19 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:XBIO) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our Partners100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
